Piper Jaffray Maintains a Neutral Rating on Qiagen (QGEN) Following Expanded Channel Checks

Qiagen (QGEN) Announces Receipt of FDA PMA for Therascreen EGFR Test for Use with IRESSA in NSCLC

Qiagen (NASDAQ: QGEN) received U.S. marketing (PMA) approval of its therascreen EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca' (NYSE: AZN) IRESSA (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). QIAGEN's therascreen EGFR test was approved by the Food and Drug Administration to enable doctors to identify NSCLC patients who have tumors that are positive for epidermal growth factor receptor (EGFR) mutations and therefore are eligible for treatment with... More

FDA Approves AstraZeneca's (AZN) Iressa for First-line Treatment of Patients with Type of Metastatic Lung Cancer (QGEN)

(Updated - July 13, 2015 1:34 PM EDT)

The U.S. Food and Drug Administration today approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test.

Lung cancer is the leading cause of cancer-related death among men and women in the U.S. and, though more common in men, the number of deaths from lung cancer in women is increasing. According to the National Cancer Institute, an estimated 221,200 Americans will be diagnosed with lung cancer, and... More

Pre-Open Stock Movers 07/10: (ICLD) (CVC) (SYT) Higher; (CUDA) (HELE) (DOV) Lower (more...)

Barracuda Networks (NYSE: CUDA) 17% LOWER; reported Q1 EPS of $0.09, $0.01 better than the analyst estimate of $0.08. Revenue for the quarter came in at $78 million versus the consensus estimate of $77.25 million. For the first quarter of fiscal 2016, gross billings grew to $94.3 million, up from $87.6 million in the first quarter of fiscal 2015.

InterCloud Systems (NASDAQ:... More

CMS Endorses Combined Pap/HPV Testing, Piper Jaffray Notes (HOLX) (QGEN) (BDX)

Piper Jaffray analyst William Quirk noted that the CMS will cover combined HPV and pap smear testing once every five years, with a screening interval above current pap guidelines (3 years). The news is viewed positive for Hologic (NASDAQ: HOLX), Qiagen (NASDAQ:... More